1 / 5

Pipeline Review of Protein Kinase C Epsilon Type

Protein Kinase C Epsilon market can be segmented by therapy, by route of administration and drug class. In the terms of therapy, it is classified into monotherapy & combination therapy. The combination therapy offers a wide therapeutic range, thus the segment is showing high acceptance. The Protein Kinase C Epsilon market report also covers pipeline products which are based on various stages of development ranging from pre-registration till discovery and undisclosed stages. For more info visit the below URL<br>http://www.marketresearchhub.com/report/protein-kinase-c-epsilon-type-npkc-epsilon-or-prkce-or-ec-271113-pipeline-review-h2-2016-report.html<br>

markresearch
Download Presentation

Pipeline Review of Protein Kinase C Epsilon Type

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pipeline Review of Protein Kinase C Epsilon Type Examined in Latest Report, H2 2016 N N N No o o o o o o of f f f P P P Pa a a ag g g ge e e es s s s – – 4 47 7 P P P Pu u u ub b b bl l l li i i is s s sh h h hi i i in n n ng g g g D D D Da a a at t t te e e e - - O Oc ct to ob be er r, , 2 20 01 16 6 B B B Br r r ro o o ow w w ws s s se e e e d d d de e e et t t ta a a ai i i il l l le e e ed d d d T T T TO O O OC C C C, , , , T T T Ta a a ab b b bl l l le e e es s s s, , , , F F F Fi i i ig g g gu u u ur r r re e e es s s s, , , , a a a an n n nd d d d C C C Ch h h ha a a ar r r rt t t ts s s s i i i in n n n G G G Gl l l lo o o ob b b ba a a al l l l S S S Se e e er r r ri i i ia a a al l l l D D D De e e ev v v vi i i ic c c ce e e e S S S Se e e er r r rv v v ve e e er r r r C C C Co o o on n n ns s s su u u um m m mp p p pt t t ti i i io o o on n n n 2 2 2 20 0 0 01 1 1 16 6 6 6 M M M Ma a a ar r r rk k k ke e e et t t t R R R Re e e es s s se e e ea a a ar r r rc c c ch h h h R R R Re e e ep p p po o o or r r rt t t t a a a at t t t: : : : http://www.marketresearchhub.com/report/protein-kinase-c-epsilon-type-npkc-epsilon-or-prkce-or-ec-271113- pipeline-review-h2-2016-report.html A latest report by Global Market Direct has been added to the broad database of Market Research Hub, titled “Protein Kinase C Epsilon Type –Pipeline Review, H2 2016”. It delivers comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics with analysis by indications, stage of development, mechanism of action (MoA), and molecule type. It also reviews key players involved in Protein Kinase C Epsilon Type targeted therapeutics development, features inactive and discontinued projects along with latest news & press releases from company/university websites and industry specific third party sources. Protein Kinase C Epsilon market Protein Kinase C Epsilon market can be segmented by therapy, by route of administration and drug class. In the terms of therapy, it is classified into monotherapy & combination therapy. The combination therapy offers a wide therapeutic range, thus the segment is showing high acceptance. The Protein Kinase C Epsilon market report Protein Kinase C Epsilon market report also covers pipeline products which are based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

  2. T T T Ta a a ab b b bl l l le e e e o o o of f f f C C C Co o o on n n nt t t te e e en n n nt t t ts s s s Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Overview 6 Therapeutics Development 7 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Products under Development by Stage of Development 7 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Products under Development by Therapy Area 8 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Products under Development by Indication 9 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Products under Development by Companies 12 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development 20 Hadasit Medical Research Services & Development Ltd 20 VM Discovery, Inc. 21 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles 22 Bryostatin-1 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 DHACP-6 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 29 Product Description 29 Request for Free Sample Report

  3. Mechanism Of Action 29 R&D Progress 29 Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 VMD-1201 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 VMD-2202 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Projects 34 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products 35 Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Featured News & Press Releases 36 Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead 36 Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes 36 Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease 37 Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model 38 Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimers Disease 38 Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimers Disease 39 Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimers Disease 39 Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference 40 Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease 40 Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann- Pick Type C 41 Apr 16, 2015: Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre- Clinical Fragile X Syndrome Behavioral Studies 42 Apr 09, 2015: Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome 42 Request for Free Sample Report

  4. Apr 06, 2015: Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease 43 Mar 30, 2015: Severe Alzheimer's Patient Responds to Bryostatin Treatment 44 Mar 17, 2015: Neurotrope Announces Positive Final Results from Its Phase 2a Safety Study for the Treatment of Alzheimers Disease 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47 R R R Re e e ep p p po o o or r r rt t t t D D D De e e et t t ta a a ai i i il l l ls s s s – – D D D Da a a at t t te e e e o o o of f f f P P P Pu u u ub b b bl l l li i i is s s sh h h hi i i in n n ng g g g – – O Oc ct to ob be er r, , 2 20 01 16 6 N N N No o o o o o o of f f f P P P Pa a a ag g g ge e e es s s s – – 4 47 7 S S S Si i i in n n ng g g gl l l le e e e U U U Us s s se e e er r r r L L L Li i i ic c c ce e e en n n ns s s se e e e – – $ $3 35 50 00 0 M M M Mu u u ul l l lt t t ti i i ip p p pl l l le e e e U U U Us s s se e e er r r r L L L Li i i ic c c ce e e en n n ns s s se e e e – – $ $7 70 00 00 0 A A A Ab b b bo o o ou u u ut t t t M M M Ma a a ar r r rk k k ke e e et t t t R R R Re e e es s s se e e ea a a ar r r rc c c ch h h h H H H HU U U UB B B B : : : : M Ma ar rk ke et t R Re es se ea ar rc ch h H HU UB B i is s t th he e c cr re ed di ib bl le e s so ou ur rc ce e f fo or r g ga ai in ni in ng g t th he e m ma ar rk ke et t r re es se ea ar rc ch h r re ep po or rt ts s t th ha at t w wi il ll l e ex xp po on ne en nt ti ia al ll ly y a ac cc ce el le er ra at te e y yo ou ur r b bu us si in ne es ss s. . W l le ea ad di in ng g r re ep po or rt t r re es se el ll le er rs s i in n t th he e b bu us si in ne es ss s w wo or rl ld d c co om mm mi it tt te ed d t to ow wa ar rd ds s o op pt ti im mi iz zi in ng g y yo ou ur r b bu us si in ne es ss s. . T Th he e r re ep po or rt ts s w we e p pr ro ov vi id de e a ar re e b ba as se ed d o on n a a r re es se ea ar rc ch h t th ha at t c co ov ve er rs s a a m ma ag gn ni it tu ud de e o of f f fa ac ct to or rs s s su uc ch h a as s t te ec ch hn no ol lo og gi ic ca al l e ev vo ol lu ut ti io on n, , e ec co on no om mi ic c s sh hi if ft ts s a an nd d a a d de et ta ai il le ed d s st tu ud dy y o of f m ma ar rk ke et t s se eg gm me en nt ts s. . Buy Report Now! We e a ar re e a am mo on ng g t th he e

  5. C C C Co o o on n n nt t t ta a a ac c c ct t t t– – – – 90 State 90 State Street, Albany, NY 12207, Albany, NY 12207, United States United States Toll Free : 866 Toll Free : 866- -997 Tel : +1 Tel : +1- -518 518- -621 Email : Email : mailto:sales@marketresearchhub.com mailto:sales@marketresearchhub.com Website : Website : http://www.marketresearchhub.com/ http://www.marketresearchhub.com/ Street, 997- -4948 (US 4948 (US- -Canada) 621- -2074 2074 Canada)

More Related